BRCA1 expression is required for efficacy of vinorelbine and is a predictive biomarker in malignant mesothelioma

被引：0
|
作者：
Busacca, S. [1 ]
Sheaff, M. [1 ]
Gray, S. G. [1 ]
O'Byrne, K. J. [1 ]
Kerr, K. [1 ]
Schmitt-Opitz, I. [1 ]
Soltermann, A. [1 ]
Pass, H. [1 ]
Quinn, J. E. [1 ]
Fennell, D. A. [1 ]
机构：
[1] Ctr Canc Res & Cell Biol, Belfast, Antrim, North Ireland
来源：
EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷
关键词：
D O I：
10.1016/S0959-8049(11)72632-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S12 / S12
页数：1
相关论文
共 50 条
  • [1] BRCA1 expression and efficacy of vinorelbine in malignant mesothelioma
    Busacca, S.
    Gray, S. G.
    Paul, I.
    McTavish, N.
    O'Byrne, K. J.
    Quinn, J. E.
    Fennell, D. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [2] BRCA1 REGULATES APOPTOSIS INDUCED BY VINORELBINE IN MALIGNANT MESOTHELIOMA
    Busacca, Sara
    Paul, Ian
    Mctavish, Niall
    Kerr, Keith M.
    Sheaff, Michael
    Quinn, Jennifer E.
    Fennell, Dean A.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S747 - S747
  • [3] BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma
    Busacca, Sara
    Sheaff, Michael
    Arthur, Kenneth
    Gray, Steven G.
    O'Byrne, Kenneth J.
    Richard, Derek J.
    Soltermann, Alex
    Opitz, Isabelle
    Pass, Harvey
    Harkin, D. Paul
    Quinn, Jennifer E.
    Fennell, Dean A.
    JOURNAL OF PATHOLOGY, 2012, 227 (02): : 200 - 208
  • [4] A biomarker profile for predicting efficacy of cisplatin–vinorelbine therapy in malignant pleural mesothelioma
    Zarah Glad Zimling
    Jens Benn Sørensen
    Thomas Alexander Gerds
    Cecilia Bech
    Claus Bøgelund Andersen
    Eric Santoni-Rugiu
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 743 - 754
  • [5] A biomarker profile for predicting efficacy of cisplatin-vinorelbine therapy in malignant pleural mesothelioma
    Zimling, Zarah Glad
    Sorensen, Jens Benn
    Gerds, Thomas Alexander
    Bech, Cecilia
    Andersen, Claus Bogelund
    Santoni-Rugiu, Eric
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (05) : 743 - 754
  • [6] BRCA1, a potential predictive biomarker in the treatment of breast cancer
    James, Colin R.
    Quinn, Jennifer E.
    Mullan, Paul B.
    Johnston, Patrick G.
    Harkin, D. Paul
    ONCOLOGIST, 2007, 12 (02): : 142 - 150
  • [7] BRCA1 expression in benign and malignant breast lesions
    Fernandez, Angel
    Reigosa, Aldo
    INVESTIGACION CLINICA, 2016, 57 (04): : 330 - 351
  • [8] The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma
    Stebbing, Justin
    Powles, Thomas
    McPherson, Kirsty
    Shamash, Jonathan
    Wells, Paula
    Sheaff, Michael T.
    Slater, Sarah
    Rudd, Robin M.
    Fennell, Dean
    Steele, Jeremy P. C.
    LUNG CANCER, 2009, 63 (01) : 94 - 97
  • [9] ATTITUDES TO PREDICTIVE TESTING FOR BRCA1
    MOHAMMED, S
    BARNES, C
    WATTS, S
    MICHIE, S
    HODGSON, S
    JOURNAL OF MEDICAL GENETICS, 1995, 32 (02) : 140 - 140
  • [10] BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in Mesothelioma
    Busacca, Sara
    O'Regan, Laura
    Singh, Anita
    Sharkey, Annabel J.
    Dawson, Alan G.
    Dzialo, Joanna
    Parsons, Aimee
    Kumar, Neelam
    Schunselaar, Laurel M.
    Guppy, Naomi
    Nakas, Apostolos
    Sheaff, Michael
    Mansfield, Aaron S.
    Janes, Sam M.
    Baas, Paul
    Fry, Andrew M.
    Fennell, Dean A.
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (02) : 379 - 388
12345